| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
|
J Am Coll Cardiol
|
2007
|
2.38
|
|
2
|
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
|
Circ Heart Fail
|
2008
|
1.65
|
|
3
|
QTc interval prolongation associated with intravenous methadone.
|
Pain
|
2003
|
1.40
|
|
4
|
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
|
J Hypertens
|
2008
|
1.22
|
|
5
|
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
|
Hypertension
|
2007
|
1.16
|
|
6
|
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.
|
J Clin Hypertens (Greenwich)
|
2007
|
0.98
|
|
7
|
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
|
J Renin Angiotensin Aldosterone Syst
|
2009
|
0.95
|
|
8
|
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension.
|
Hypertens Res
|
2006
|
0.95
|
|
9
|
Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.
|
J Clin Hypertens (Greenwich)
|
2010
|
0.93
|
|
10
|
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
|
J Renin Angiotensin Aldosterone Syst
|
2008
|
0.86
|
|
11
|
Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
|
J Hypertens
|
2009
|
0.84
|
|
12
|
Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
|
Cardiovasc Ther
|
2010
|
0.82
|
|
13
|
Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.
|
J Clin Hypertens (Greenwich)
|
2011
|
0.79
|
|
14
|
Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
|
Clin Ther
|
2009
|
0.79
|
|
15
|
Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
|
J Clin Pharmacol
|
2010
|
0.78
|
|
16
|
Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
|
J Clin Hypertens (Greenwich)
|
2011
|
0.77
|
|
17
|
Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
|
Hypertens Res
|
2009
|
0.76
|
|
18
|
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
|
Clin Drug Investig
|
2011
|
0.76
|
|
19
|
Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation study.
|
J Clin Pharmacol
|
2011
|
0.76
|
|
20
|
Antihypertensive treatment in patients with class 3 obesity.
|
Ther Adv Endocrinol Metab
|
2012
|
0.75
|